- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - Lynparza significantly delayed disease progression
AnnouncementREG - AstraZeneca PLC - Brilinta's PhIII THEMIS trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - AstraZeneca Full-Year and Q4 2018 Results
AnnouncementREG - AstraZeneca PLC - US FDA grants Fasenra Orphan Drug Designation
AnnouncementREG - AstraZeneca PLC - US FDA grants Breakthrough Therapy Designation
AnnouncementREG - AstraZeneca PLC - EMA grants PRIME eligibility for MEDI8897
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Forxiga receives positive EU CHMP opinion
AnnouncementREG - AstraZeneca PLC - Completion of divestment of US Synagis rights
AnnouncementREG - AstraZeneca PLC - AstraZeneca announces organisational changes
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Bevespi Aerosphere approved in the EU for COPD
AnnouncementREG - AstraZeneca PLC - Lynparza meets primary endpoint in SOLO-3 trial
AnnouncementREG - AstraZeneca PLC - Phase III ROCKIES and OLYMPUS roxadustat trials
AnnouncementREG - AstraZeneca PLC - FDA approves Lynparza as 1L maintenance therapy
AnnouncementREG - AstraZeneca PLC - Roxadustat approved in China for the treatment of
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Update on the Phase III EAGLE trial of Imfinzi
AnnouncementREG - AstraZeneca PLC - Divestment of rights to Covis completed
Announcement